Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from CSPC Pharmaceutical Group ( (HK:1093) ) is now available.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to begin clinical trials of its Daratumumab Injection, a biosimilar to the multiple myeloma drug Darzalex, for use in adult patients. Developed as a Class 3.3 therapeutic biological product, the antibody drug has shown high similarity to the reference medicine in quality, safety and efficacy in preclinical studies, clearing a key regulatory hurdle that could strengthen CSPC’s position in the domestic oncology biosimilars market if subsequent clinical trials are successful.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$12.40 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited is a Hong Kong-incorporated pharmaceutical company engaged in the research, development and production of innovative and generic medicines, with a growing focus on biologics. The group develops therapeutic products for major disease areas, including oncology, to address demand in the Chinese healthcare market and beyond.
Average Trading Volume: 121,615,657
Technical Sentiment Signal: Buy
Current Market Cap: HK$94.33B
See more insights into 1093 stock on TipRanks’ Stock Analysis page.